Single-Center, Double-Blind, Randomized, Placebo-Controlled, Study of the Efficacy and Safety of a Cream Formulation for Improving Facial Wrinkles and Skin Quality.

Introduction: Several therapeutic modalities from topicals to chemical peels and energy-based devices are available to improve skin quality and reduce the appearance of wrinkles in the face and neck area.

Objective: The objective of this single-center, double blinded, placebo-controlled study was to evaluate the safety and efficacy of Nimni Cream by Hydropeptide® on skin quality and wrinkles.

Methods: 20 patients were randomized in a 3:1 ratio to use either Nimni Cream by Hydropeptide or placebo starting with twice a week application and increasing to daily for 8 weeks.

Double Blind, Placebo Controlled Evaluation of a Novel Skin Lightening Agent.

Melasma remains a troubling problem for physicans and patients alike. It is a chronic irregular, symmetric hyperpigmentation seen most often in women. In this study, a unique combination of ingredients with non-irritating properties was tested for treatment of melasma.

Sumoylation modulates a domain in CTCF that activates transcription and decondenses chromatin.

CTCF is a multipurpose transcription factor with activation, repression, and insulator activity. It also participates in regulating chromatin architecture by maintaining open chromatin and mediating long-range chromosomal interactions. Participation by CTCF in such diverse processes suggests that it has multiple functional domains that regulate transcription and modify chromatin structure.